Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
The acyclic purine nucleoside analog, 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242) and its orally active diacetate ester prodrug (HOE961) were reported to be potent inhibitors of vaccinia virus replication in cell culture and in infected mice. These compounds were evaluated further, using infections with the related cowpox virus. Against a wild-type (WT) cowpox virus strain in mouse C127I cell culture, 50% effective concentrations (EC(50), determined by plaque reduction assays) of S2242 and cidofovir (a positive control) were 3.5 and 1.0 microM, respectively. EC(50) values obtained against a cidofovir-resistant strain of the virus were 33 and 230 microM, respectively. Compounds were at least ten-fold less potent against WT virus in Vero cells than C127I cells. S2242 and cidofovir were 50% inhibitory to the proliferation of uninfected C127I cells at 340 and 180 microM, respectively, but neither compound inhibited Vero cell growth at 1000 microM. Mice were lethally infected with cowpox virus by intranasal inoculation, followed 24 h later by antiviral treatment for 5 consecutive days. Once or twice daily intraperitoneal (i.p.) treatments with either S2242 or HOE961 at 100 mg/kg per day resulted in > or = 70 survival compared with no survivors in the placebo group. Lower doses of these compounds (10 and 30 mg/kg per day) were not protective, however. Cidofovir was 100% protective at 30 mg/kg per day. A 10-day course of treatment gave comparable survival results and demonstrated the oral efficacy of HOE961. Treatments with S2242 (100 mg/kg per day) and cidofovir (30 mg/kg per day) each reduced lung and nasal virus titers by approximately ten-fold, whereas, HOE961 (100 mg/kg per day) was less active. Overall, S2242 and HOE961 were found to be effective against cowpox virus infections in mice but were less potent than cidofovir. Since, HOE961 was orally active, it may have advantages over the other parenterally administered compounds for treating orthopoxvirus infections.
Smee
Donald F
DF
Department of Animal, Dairy and Veterinary Sciences, Institute for Antiviral Research, Utah State University, 84322-5600, Logan, UT 84322-5600, USA. dsmee@cc.usu.eud
Bailey
Kevin W
KW
Sidwell
Robert W
RW
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D019540:Area Under Curve; D001835:Body Weight; D002522:Chlorocebus aethiops; D000077404:Cidofovir; D015605:Cowpox / Q000188:drug therapy*; D015608:Cowpox virus / Q000254:growth & development* / Q000378:metabolism; D003596:Cytosine / Q000031:analogs & derivatives / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D008168:Lung / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000821:virology; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology; D011355:Prodrugs / Q000494:pharmacology*; D011687:Purines / Q000494:pharmacology*; D018709:Statistics, Nonparametric; D014709:Vero Cells
D000998:Antiviral Agents; C096889:HOE 961; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011355:Prodrugs; D011687:Purines; C092709:S 2242; D003596:Cytosine; D000077404:Cidofovir